To announce the press release for the Company's
press conference on material information today
Date of events
2022/06/14
To which item it meets
paragraph 53
Statement
1.Date of occurrence of the event:2022/06/14
2.Company name:Bora Pharmaceuticals Co., Ltd.
3.Relationship to the Company (please enter "head office" or
"subsidiaries"):Head office
4.Reciprocal shareholding ratios:Not applicable
5.Cause of occurrence:The Company hosts a press conference at
Taipei Exchange on 2022/06/14 to present the following
information:
Bora Pharmaceuticals Co., Ltd (6472.TWO) announced the
acquisition of TWi Pharmaceuticals, Inc. for approximately
NT$6 billion. With a focus on growing its presence in the
horizontal integration of CDMO as one of the firm's
long-term strategic goals, Bora Pharmaceuticals says TWi
Pharmaceuticals is a leading specialty pharmaceutical
manufacturer in Taiwan possessing high technical development
and manufacturing technologies alongside successful
commercialization of specialty generics for niche markets.
The acquisition will greatly strengthen Bora's CDMO
capabilities and distribution network and empower Bora's
revenue and operating performance. TWi Pharmaceuticals is
an international generic drug company which focus on North
America, Taiwan, Europe and China market. TWi Pharmaceuticals
has deep knowledge on US regulation, market competitiveness,
and technical analysis.
6.Countermeasures:No
7.Any other matters that need to be specified:No
Attachments
Original Link
Original Document
Permalink
Disclaimer
Bora Pharmaceuticals Co. Ltd. published this content on 14 June 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 June 2022 13:42:09 UTC.
Bora Pharmaceuticals Co Ltd is a Taiwan-based company principally engaged in the agency and sales of western medicines, as well as the research, development, manufacture and sales of new drugs and health products. The Company's main products are categorized into prescription drugs and health care products, including central nervous drugs, cardiovascular drugs, antibiotics, antiviral agents, ophthalmic drugs, gastrointestinal drugs, foam ingots and health care products. In addition, the Company has biopharmaceutical technologies related to the development of cell lines for the production of protein drugs, the development and analysis of upstream and downstream processes, as well as the establishment of quality control and testing specifications and the creation of cell banks.
BORA PHARMACEUTICALS CO., LTD. 
